Atorvastatin Calcium

證據等級: L5

預測適應症: 0 個

Atorvastatin Calcium: Drug Repurposing Assessment — TxGNN Prediction Data Pending

One-Sentence Summary

Atorvastatin Calcium is a widely-used statin originally indicated for hyperlipidaemia and cardiovascular risk reduction via HMG-CoA reductase inhibition. The current Evidence Pack does not contain TxGNN prediction output — the predicted_indications array is empty — meaning no new repurposing indication can be evaluated at this time. With 71 registered products in Malaysia and key safety and MOA data still outstanding, the repurposing evaluation is blocked until upstream data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Hyperlipidaemia / Cardiovascular risk reduction (well-established; TFDA indication text not yet retrieved)
Predicted New Indication	— (No TxGNN output available)
TxGNN Prediction Score	— (Pending)
Evidence Level	— (Cannot be determined)
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	71
Recommended Decision	Hold

Why is This Prediction Reasonable?

TxGNN prediction data is not yet available in this Evidence Pack (predicted_indications: []), so no mechanism-to-indication bridging analysis can be performed at this stage.

From established pharmaceutical knowledge, atorvastatin is an HMG-CoA reductase inhibitor (statin). Beyond lipid-lowering, statins are widely researched for pleiotropic effects — including anti-inflammatory, anti-proliferative, and neuroprotective properties — which have driven repurposing hypotheses in areas such as neurodegenerative disease, sepsis, and certain cancers. However, these hypotheses cannot be confirmed or scored without the TxGNN model output.

Formal mechanism-to-indication analysis will be completed once the TxGNN prediction pipeline is executed and DrugBank MOA data is retrieved.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

Note: This reflects missing predicted_indications data — not the absence of real-world trial activity for atorvastatin. Once a target indication is identified by TxGNN, a ClinicalTrials.gov search should be conducted.

Literature Evidence

Currently no related literature available in this Evidence Pack.

Note: Same reason as above — literature evidence retrieval is tied to a specific predicted indication, which is not yet available.

Malaysia Market Information

The Evidence Pack confirms 71 registered products for ATORVASTATIN CALCIUM in Malaysia. However, individual product details (authorization number, product name, dosage form, approved indication) were not returned in the current data pull.

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not retrieved)	(Not retrieved)	(Not retrieved)	(Not retrieved)

Action Required: Re-run the NPRA/BPFK query with full licence-level detail retrieval. With 71 registrations confirmed, this data should be accessible.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug-drug interactions) returned as data gaps or were not found in the current query. A TFDA/NPRA package insert (PIL/SmPC) retrieval is required before any safety-gated decision can be made.

Conclusion and Next Steps

Decision: Hold

Rationale: The core repurposing analysis cannot proceed because the TxGNN prediction pipeline has not returned output for this candidate, and two blocking data gaps (safety/MOA) remain unresolved. The drug is well-established in the market (71 Malaysia registrations), so regulatory feasibility is strong once a prediction target is confirmed.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve TFDA/NPRA package insert: download SmPC/PIL PDF from the NPRA official portal and parse key warnings and contraindications
[DG002 — High] Retrieve DrugBank MOA: query DrugBank API using the resolved DrugBank ID (TFDA → DrugBank ID mapping was attempted; ensure the mapping result is written to drug.drugbank_id)
[Critical] Execute TxGNN prediction pipeline for ATORVASTATIN CALCIUM to populate predicted_indications — this is the prerequisite for the entire repurposing evaluation
Retrieve full NPRA licence-level details (product name, dosage form, indication text) for the 71 registered products
Re-run DDI query after DrugBank ID is confirmed (current query_status: not_found likely due to missing DrugBank ID linkage)

Once the above are resolved, this report should be regenerated with Evidence Pack v5.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.